- Home
- AKA vs SAVA Comparison
AKA vs SAVA Comparison
Compare AKA & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKA
- SAVA
- Stock Information
- Founded
- AKA 2018
- SAVA 1998
- Country
- AKA United States
- SAVA United States
- Employees
- AKA N/A
- SAVA N/A
- Industry
- AKA Catalog/Specialty Distribution
- SAVA Biotechnology: Pharmaceutical Preparations
- Sector
- AKA Consumer Discretionary
- SAVA Health Care
- Exchange
- AKA Nasdaq
- SAVA Nasdaq
- Market Cap
- AKA 110.4M
- SAVA 102.4M
- IPO Year
- AKA 2021
- SAVA N/A
- Fundamental
- Price
- AKA $10.01
- SAVA $2.14
- Analyst Decision
- AKA Strong Buy
- SAVA Hold
- Analyst Count
- AKA 3
- SAVA 1
- Target Price
- AKA $24.33
- SAVA $2.00
- AVG Volume (30 Days)
- AKA 5.4K
- SAVA 599.4K
- Earning Date
- AKA 11-06-2025
- SAVA 11-06-2025
- Dividend Yield
- AKA N/A
- SAVA N/A
- EPS Growth
- AKA N/A
- SAVA N/A
- EPS
- AKA N/A
- SAVA N/A
- Revenue
- AKA $598,107,000.00
- SAVA N/A
- Revenue This Year
- AKA $7.23
- SAVA N/A
- Revenue Next Year
- AKA $4.04
- SAVA N/A
- P/E Ratio
- AKA N/A
- SAVA N/A
- Revenue Growth
- AKA 7.67
- SAVA N/A
- 52 Week Low
- AKA $7.00
- SAVA $1.15
- 52 Week High
- AKA $32.25
- SAVA $33.98
- Technical
- Relative Strength Index (RSI)
- AKA 37.66
- SAVA 44.70
- Support Level
- AKA $10.42
- SAVA $2.12
- Resistance Level
- AKA $10.99
- SAVA $2.40
- Average True Range (ATR)
- AKA 0.44
- SAVA 0.10
- MACD
- AKA -0.06
- SAVA -0.02
- Stochastic Oscillator
- AKA 0.00
- SAVA 10.34
About AKA a.k.a. Brands Holding Corp.
a.k.a. Brands Holding Corp is an online fashion retailer focused on acquiring and accelerating the growth of next-generation, digitally native fashion brands targeting Gen Z and Millennial customers. The brands of the company are two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company derives maximum revenue from Australia/New Zealand.
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.